Metabolomics-Based Systems Biology and Personalized Medicine: Moving Towards n = 1 Clinical Trials?

• Burrill & Company: Life Sciences – a changing prescription. Burrill Media group, CA, USA (2006).
   Google Scholar
• Ginsburg GS , KonstanceRP, AllsbrookJS, SchulmanKA: Implications of pharmacogenomics for drug development and clinical practice.Arch. Intern. Med.165(20) , 2331–2336 (2005).
   PubMed Web of Science ®Google Scholar
• Wang M , LamersRJ, KorthoutHA et al.: Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. J. Phytother. Res.19(3) , 173–182 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Greef J , McBurneyRN: Rescuing drug discovery and drug development: in vivo systems pathology and systems pharmacology.Nat. Rev. Drug Discov.4 , 961–967 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Greef J , AdourianA, MuntendamP, McBurneyRN: Lost in translation? Role of metabolomics in solving translational problems in drug discovery and development.Drug Discovery Today: Technologies (2006) (In press).
   Google Scholar
• Abrahams E , GinsburgGS, SilverM: The Personalized Medicine Coalition: goals and strategies.Am. J. Pharmacogenomics5(6) , 345–355 (2005).
   PubMedGoogle Scholar
• Bren L : Metabolomics: working towards personalized medicine.FDA Consumer Magazine6 , 29–33 (2005).
   Google Scholar
• Nebert DW , Jorge-NebertL, VesellES: Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements.Am. J. Pharmacogenomics3(6) , 361–370 (2003).
   PubMedGoogle Scholar
• Clish CB , DavidovE, OresicM et al.: Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS8(1) , 3–13 (2004).
   PubMed Web of Science ®Google Scholar
• Davidov E , ClishCB, OresicM et al.: Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. OMICS8(4) , 267–288 (2004).
   PubMed Web of Science ®Google Scholar
• Oresic M , ClishCB, DavidovEJ et al.: Phenotype characterisation using integrated gene transcript, protein and metabolite profiling. Appl. Bioinformatics3(4) , 205–217 (2004).
   PubMedGoogle Scholar
• Susztak K , BottingerEP: Diabetic nephropathy: a frontier for personalized medicine.J. Am. Soc. Nephrol.17(2) , 361–367 (2006).
   PubMed Web of Science ®Google Scholar
• Glocker MO , GuthkeR, KekowJ, Thiesen HJ: Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine. Med. Res. Rev.26(1) , 63–87 (2006).
   PubMed Web of Science ®Google Scholar
• Raamsdonk LM , TeusinkB, BroadhurstD et al.: A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol.19(1) , 45–50 (2001).
   PubMed Web of Science ®Google Scholar
• Griffin JL : Metabolic profiles to define the genome: can we hear the phenotypes?Philos. Trans. R. Soc. Lond. B. Biol. Sci.359(1446) , 857–871 (2004).
   PubMed Web of Science ®Google Scholar
• German JB , WatkinsSM, FayLB: Metabolomics in practice: emerging knowledge to guide future dietetic advice toward individualized health.J. Am. Diet Assoc.105(9) , 1425–1432 (2005).
   PubMedGoogle Scholar
• Zeisel SH , FreakeHC, BaumanDE et al.: The nutritional phenotype in the age of metabolomics. J. Nutr.135(7) , 1613–1616 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Greef J , TasAC, BouwmanJ, Ten Noever de Brauw MC, Schreurs WHP: Evaluation of field-desorption and fast atom-bombardement mass spectrometric profiles by pattern recognition techniques. Anal. Chim. Acta150 , 45–52 (1983).
   Web of Science ®Google Scholar
• Bollard ME , StanleyEG, LindonJC, NicholsonJK, HolmesE: NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition.NMR Biomed.18(3) , 143–162 (2005).
   PubMed Web of Science ®Google Scholar
• Kochhar S , JacobsDM, RamadanZ, BerruexF, FuerholzA, FayLB: Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics.Anal. Biochem.352(2) , 274–281 (2006).
   PubMed Web of Science ®Google Scholar
• Plumb RS , GrangerJH, StumpfCL et al.: A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst130(6) , 844–849 (2005).
   PubMed Web of Science ®Google Scholar
• Robosky LC , WellsDF, EgnashLA, ManningML, ReilyMD, RobertsonDG: Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) rats.Toxicol. Sci.87(1) , 277–284 (2005).
   PubMed Web of Science ®Google Scholar
• Dumas ME , MaibaumEC, TeagueC et al.: Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. Anal. Chem.78(7) , 2199–2208 (2006).
   PubMed Web of Science ®Google Scholar
• Lenz EM , BrightJ, WilsonID et al.: Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal.36(4) , 841–849 (2004).
   PubMed Web of Science ®Google Scholar
• Holmes E , NicholsonJ: Variation in gut microbiota strongly influences individual rodent phenotypes.Toxicol. Sci.87(1) , 277–284 (2005).
   PubMed Web of Science ®Google Scholar
• van der Greef J , VerheijER, VogelsJ, van der Heijden R, Davidov E, Naylor S: The role of metabolomics in systems biology, a new vision for drug discovery and development. In: Metabolic Profiling: Its role in biomarker discovery and gene function analysis. Harrigan GG, Goodacre R (Eds). Kluwer Academic Publishing, Boston, MA, USA, 170–198 (2003).
   Google Scholar
• Brindle JT , AnttiH, HolmesE et al.: Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med.8(12) , 1439–1444 (2002).
   PubMed Web of Science ®Google Scholar
• Kirschenlohr HL , GriffinJL, ClarkeSC et al.: Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med.12 , 705–710 (2006).
   PubMed Web of Science ®Google Scholar
• Clayton TA , LindonJC, CloarecO et al.: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature440(7087) , 1073–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Nicholson JK , HolmesE, WilsonID: Gut microorganisms, mammalian metabolism and personalized health care.Nat. Rev. Microbiol.3(5) , 431–438 (2005).
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R : From biomarkers and disease mechanisms to Pharmacometabolomics and personalized therapy. Presented at:Second Scientific meeting of the Metabolomics Society, Boston, USA, June 24–29, (2006).
   Google Scholar
• Gerszten R : Metabolomic analysis of planned myocardial injury: insights into biomarkers and pathways. Presented at:Second Scientific meeting of the Metabolomics Society, Boston, USA, June 24–29, (2006).
   Google Scholar
• Watters JW , McLeodHL: Cancer pharmacogenomics: current and future applications.Biochim. Biophys. Acta1603(2) , 99–111 (2003).
   PubMed Web of Science ®Google Scholar
• Van der Greef J , StroobantP, van der Heijden R: The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol.8(5) , 559–565 (2004).
   PubMed Web of Science ®Google Scholar
• Grant DM , TangBK, KalowW: A simple test for acetylator phenotype using caffeine.Br. J. Clin. Pharmacol.58(7) , S788–S793 (2004).
   PubMedGoogle Scholar
• Sabatine MS , LiuE, MorrowDA et al.: Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation112(25) , 3868–3875 (2005).
   PubMed Web of Science ®Google Scholar
• Van der Greef J : Systems biology, connectivity and the future of medicine.IEE Proc., Syst. Biol.152(4) , 174–178 (2005).
   Google Scholar
• Snyderman R , YoedionoZ: Prospective care: a personalized, preventative approach to medicine.Pharmacogenomics7(1) , 5–9 (2006).
   PubMed Web of Science ®Google Scholar
• Bar-Yam Y :Making things work, solving complex problems in a complex world. Knowledge press, MA, USA. (2004)
   Google Scholar

Website

• Institute for Alternative Futures, The 2029 project: Achieving an ethical future in biomedical R&D: Alexandria, Virginia, (2005). www.altfutures.com
   Google Scholar